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Abstract
During routine yearly physicals, primary care providers often
evaluate serum laboratory lipid levels. Many of these
patients have no past medical history of cardiovascular
events related to atherosclerotic disease. Some patients do
not have secondary risk factors, such as diabetes mellitus or
smoking history.

Literature Review
2013 ACC/AHA Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in
Adults – PRIMARY PREVENTION

Previous cardiovascular events provide stronger indications for
the use of HMG-CoA reductase inhibitors (statins). In the
absence of these, the provider may turn to current
guidelines, in this case the 2013 the American College of
Cardiology and the American Heart Association published
the 2013 ACC/AHA Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in
Adults.

4D- “Atorvastatin had no significant effect on the
individual components of the primary end point.”
ALERT- “Total mortality and graft loss did not differ
significantly between groups.”
ALLHAT-LLT – “All-cause mortality was similar for
the 2 groups.”
ASCOT-LLA – “All-cause mortality was nonsignificantly reduced”
ASPEN – “Composite end point reductions were not
statistically significant.”
AURORA – “Rosuvastatin had no benefit in any
subgroup examined, including patients with diabetes”
MEGA – “Although treatment with pravastatin was
associated with lower total mortality than with diet
alone, this result was not significant”

There is however, controversy, even within the evidence to
this guideline, about the effect of statins in primary
prevention with respect to the reduction that they have on
all-cause mortality. There are many factors that could
influence the use of statin therapy for primary prevention.
These could include non-fatal myocardial infarction, nonfatal cerebral vascular accident, among others. One of the
biggest factors is all-cause mortality.
A review of the evidence cited for these guidelines
demonstrates that the majority of the clinical trials did not
show a reduction in all-cause mortality, in primary
prevention. It is important to understand that this evidence
comes directly from the same evidence that the ACC/AHA
used to create the primary prevention guidelines.

Statement of the Problem
ALL-CAUSE MORTALITY in PRIMARY PREVENTION
• Without factoring in any other data sets, evidence is
controversial.
• By only focusing on one specific factor, the hope is to
paint a clear picture of that factor, thereby facilitating a
better decision making process.
• All-cause mortality is one of the end points that is most
easily tracked without interruption needed.

JUPITER – “Rosuvastatin also significantly reduced
the incidence of death from any cause.”
AFCAPS/TexCAPS – “Rates for overall mortality,
cardiovascular mortality, noncardiovascular mortality,
and fatal cancer were low, and there were no
treatment group differences.”
CARDS – “We recorded a 27% fall in all-cause
mortality in patients allocated atorvastatin.”
WOSCOPS- “treating 1000 middle-aged …
pravastatin for five years will result in …2 fewer
deaths from other causes than would be expected in
the absence of treatment.”

Research Question
Does the use of statins, in the primary
prevention setting, without additional risk
factors, affect all-cause mortality?
The answer is that a review of the evidence used in the
2013 ACC/AHA Guideline on the Treatment of Blood
Cholesterol to Reduce Atherosclerotic Cardiovascular Risk
in Adults, the Cholesterol Treatment Trialists’ (CTT),
demonstrates more evidence that not that statin therapy
does not reduce the risk of all-cause mortality.

Discussion
26 = Number of Cholesterol Treatment Trialists’ (CTT)
11 = Number of Trials in CTTs that are actually PRIMARY
PREVENTION
3 = Number of CTT’s that show all cause mortality
REDUCTION
8 = Number of CTT’s that show NO all cause mortality
reduction
Eight out of eleven studies appears to be a wide margin of
evidence supporting no effect on all-cause mortality in the
primary prevention setting, with the use of statins.
To come to a different conclusion would be to put more
weight on the three positive studies, which would seem
unlikely to be true given the evidence

Applicability to Clinical
Practice
Cardiovascular disease would include strokes, myocardial
infarctions, arrhythmias, peripheral arterial disease, or
heart valve problems.
An event from one of these conditions can have a profound
effect on a patient’s life, but not cause death.
This is important to remember because the conclusion that
statins do not reduce all-cause mortality in the primary
prevention setting does not mean that statins will not
protect against such cardiovascular events.
Although patients may end up living about the same amount
of years, whether they take statins or not, it does not mean
that they will have a better quality of life during those
years.
Where the research from this project can be useful in the
clinical setting, especially primary care, is when patients
have difficulty with the side effects of statins
Clinicians should discuss the risks and benefits to statin
therapy before starting a regiment. This project will aid in
that discussion.

References
Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent, C., Blackwell, L.,
Emberson, J., Holland, L. E., Reith, C., . . . Collins, R. (2010). Efficacy and safety of
more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000
participants in 26 randomised trials. Lancet (London, England), 376(9753), 16701681. doi:10.1016/S0140-6736(10)61350-5 [doi]
Stone, N. J., Robinson, J., Lichtenstein, A. H., Merz, C. N. B., Blum, C. B., Eckel,
R. H., . . . Wilson, P. W. F. (2013). 2013 ACC/AHA guideline on the treatment of
blood cholesterol to reduce atherosclerotic cardiovascular risk in adults.
Circulation, doi:10.1161/01.cir.0000437738.63853.7a

Acknowledgements
I would like to acknowledge the help of Julie Percival (statistics), Jeremy Hopkin,
MD (clinical advisor), Douglas Callahan, DO (clinical advisor), Jay Metzger PA-C
(faculty advisor). Most of all I would like to acknowledge my wonder wife and
children for putting up with multiple conversations that I am sure did not interest
them, and being so understanding for all the time away from them that this project
took to complete.

